Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $109.21 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $36.20 | 4 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $32.21 | 2 | $0 (2021) |
| AbbVie Inc. | $24.46 | 2 | $0 (2021) |
| Allergan, Inc. | $16.34 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $16.89 | 1 | Genentech USA, Inc. ($16.89) |
| 2021 | $92.32 | 8 | Otsuka America Pharmaceutical, Inc. ($32.21) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/10/2022 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Virology & Specialty Care | ||||||
| 12/09/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $2.72 | General |
| Category: Virology & Specialty Care | ||||||
| 11/18/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $6.54 | General |
| Category: Virology & Specialty Care | ||||||
| 04/28/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: NEUROSCIENCE | ||||||
| 03/02/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.38 | General |
| Category: NEUROSCIENCE | ||||||
| 02/03/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: PSYCHIATRY | ||||||
| 02/02/2021 | Allergan, Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: NEUROSCIENCE | ||||||
| 01/26/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $10.05 | General |
| Category: Virology & Specialty Care | ||||||
| 01/20/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 416 | 741 | $49,304 | $16,375 |
| 2022 | 12 | 463 | 880 | $56,082 | $19,713 |
| 2021 | 9 | 157 | 327 | $14,248 | $3,742 |
| 2020 | 8 | 189 | 439 | $1,175 | $101.98 |
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 58 | $10,788 | $4,472 | 41.5% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 58 | 68 | $6,800 | $2,757 | 40.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $8,235 | $2,585 | 31.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 43 | $5,332 | $2,114 | 39.7% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 48 | 106 | $5,088 | $1,719 | 33.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 25 | 25 | $5,000 | $1,454 | 29.1% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 38 | 41 | $1,763 | $664.20 | 37.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 52 | 73 | $3,358 | $518.87 | 15.5% |
| 81003 | Automated urinalysis test | Office | 2023 | 20 | 24 | $528.00 | $52.80 | 10.0% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 13 | 60 | $1,440 | $20.45 | 1.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 46 | 216 | $972.00 | $16.77 | 1.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $8,540 | $3,418 | 40.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 46 | 49 | $6,076 | $2,927 | 48.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 26 | $4,836 | $2,516 | 52.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $5,600 | $2,496 | 44.6% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 60 | 61 | $6,100 | $2,482 | 40.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 29 | 29 | $5,800 | $1,963 | 33.8% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 55 | 110 | $5,280 | $1,796 | 34.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 61 | 110 | $5,060 | $843.24 | 16.7% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 19 | 19 | $1,900 | $671.27 | 35.3% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2022 | 32 | 32 | $1,376 | $521.19 | 37.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 46 | 190 | $4,560 | $64.36 | 1.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 47 | 212 | $954.00 | $16.42 | 1.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 13 | 13 | $2,600 | $1,132 | 43.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 16 | $2,012 | $1,039 | 51.6% |
About Haley Knight
Haley Knight is a Family healthcare provider based in Russellville, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2019. The National Provider Identifier (NPI) number assigned to this provider is 1649731829.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Haley Knight has received a total of $109.21 in payments from pharmaceutical and medical device companies, with $16.89 received in 2022. These payments were reported across 9 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($109.21).
As a Medicare-enrolled provider, Knight has provided services to 1,225 Medicare beneficiaries, totaling 2,387 services with total Medicare billing of $39,932. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Practice Information
- Specialty Family
- Location Russellville, AL
- Active Since 03/28/2019
- Last Updated 02/01/2020
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1649731829
Products in Payments
- Xofluza (Drug) $36.20
- REXULTI (Drug) $32.21
- VRAYLAR (Drug) $28.42
- UBRELVY (Drug) $12.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Russellville
Mrs. Melanie Malone, Crnp, CRNP
Family — Payments: $8,263
John Rice, Aprn, APRN
Family — Payments: $5,426
Amy Webster, Aprn, APRN
Family — Payments: $3,082
Jena Hamm, Crnp, CRNP
Family — Payments: $2,789
Erinn Basista, Dnp, Aprn, Fnp-C, DNP, APRN, FNP-C
Family — Payments: $2,566
Jessica Mcneese, Apn, APN
Family — Payments: $2,465